Objective: To assess the efficiency and tolerance of misoprostol versus oxytocin in Active Management of the Third Period of Childbirth. Framework and Method of Study: The study was carried out at the Porto-Novo university maternity in Benin. The hospital is level 3. He acted in a randomized clinical trial with a descriptive and comparative aim referred from 1st January 2017 to 31st December 2017. We included all eligible women in labor in the delivery room during the study period and at that gestational age was greater than or equal to 37 weeks of amenorrhea, delivery was done through vaginal birth and delivered with a live birth and agreed to participate in the study. The cases eligible by order of admission were grouped in blocks of two, “Misoprostol” and “Oxytocin” corresponding to the Active Management of the Third Period of delivery. The data collected were captured and analyzed using the SPSS version 20 software. For the comparison of the results, we used the chi-square statistical test and the difference was assumed to be statistically significant for a p ≤ 0 . 05. The confidentiality of parturient was respected. Results: we recorded 1234 of which were delivered via vaginal birth. The Active Management of the Third Period of Delivery was carried out in 1202 parturients. According to our inclusion criteria, 892 parturients were retained for the study, of which 446 for each group. The average age of parturients was 26.94 ± 5.65 years. Almost pregnancies were mono-fetal (95.7% vs. 93.5%). The average time to expel the placenta after utero-tonic administration was 4.05 ± 0.27 min in the “Misoprostol” group versus 3.82 ± 0.52 min in the “Oxytocin” group (p > 0.05). We had only 9 cases of placental retention in the group “Misoprostol” versus 5 cases in the “Oxytocin” group. Most of the parturients had blood loss less than 500 ml (96.2% vs. 96.6%). The frequency of delivery hemorrhage was 3.8% in the “Misoprostol” group versus 3.4% in the “Oxytocin” group. The mean blood volume lost was 284.33l ± 13.31 ml in the “ Misoprostol ” group versus 225.94 ± 21.52 ml in the “ oxytocin ” group. Maternal prognosis was generally good in both groups. Conclusion: Misoprostol may be an alternative in Active Management of the Third Period of Delivery especially in developing countries where the cold chain is often lacking.
According to WHO data in 2015 [
Appreciate the efficiency and tolerance of misoprostol versus oxytocin in Active Management of the Third Period of Childbirth.
The study was carried out at the Obstetric Gynecology Department of University hospital centerin Porto-Novo, the political capital of Benin republic. The hospital is level 3. This was a cross-sectional study with a descriptive and comparative aim with prospective data collection from January 1st, 2017 to December 1st, 2017. Were included all parturient admitted to the delivery room during the study period and in whom gestational age was greater than or equal to 37 weeks of amenorrhea (WA), delivery was with the newborn live and who agreed to participate in the study. We excluded all women in labor with known bleeding disorder or a history of hypersensitivity to misoprostol or oxytocin. The parturient eligible by order of admission in the study were grouped in blocks of two. In two sealed envelopes, we recorded the terms “Misoprostol” or “Oxytocin” respectively corresponding to the active management of the third period of delivery (AMTPD) or assisted delivery by sublingual administration of 600 μg of misoprostol or intramuscular injection of 10ui oxytocin within one minute of the expulsion of the fetus. For each pair of parturient, the first one had drawn one of the two envelopes. The envelope was then opened allowing to know to which protocol the parturient was assigned so that if this first parturient derived the protocol “Misoprostol”, the second systematically received the protocol “Oxytocin”. The efficacy of the protocol was assessed through the time of placenta expulsion, blood loss, change in hemoglobin and hematocrit between admission and 24 hours after delivery, and possible complications of delivery. Tolerance was assessed by the occurrence or absence of side effects. The data collected were captured and analyzed using the SPSS version 20 software. For the comparison of the results, we used the chi-square statistical test and the difference was assumed to be statistically significant for a p less than or equal to 0.05. The confidentiality of the data, the anonymity and the consent of the parturient were respected.
We have also the authorization from the hospital authorities and the service head.
The emergency admission in this period was 2800 patients. We recorded 2378 deliveries, 1234 of which were delivered via vaginal birth. The active management of the third period of delivery was carried out in 1202 parturients or a realization rate of 97.4%. Taking into account our inclusion criteria, 892 parturients were retained for the study, of which 446 for the group “Misoprostol” and 446 for the group “Oxytocin”.
The average age of parturients was 26.94 ± 5.65 years with extremes of 15 and 42 years (26.88 ± 5.62 vs. 27.01 ± 5.62 years, p = 0.317). The gynaecological and obstetric histories were statistically comparable between the two groups (
Almost of pregnancies were mono-fetal (95.7% vs. 93.5%) and these pregnancies were followed in most cases (90.4% vs. 92.4%). Data on pregnancy (pathologies presented during pregnancy) and childbirth (gestational age at delivery, mode of entry into labor, type of delivery, duration of Labor, birth weight) were statistically identical between the two groups (
The average time to expel the placenta after utero-tonic administration was 4.05
| Misoprostol, N (%) | Oxytocin, N (%) | p | |
|---|---|---|---|
| Gestity | 0.302 | ||
| Primigestous (1) | 118 (26.5) | 125 (28.0) | |
| Paucigestous (2 - 3) | 187 (41.9) | 170 (38.1) | |
| Multigestous (≥4) | 141 (31.6) | 151 (33.9) | |
| Parity | 0.824 | ||
| Nulliparous (O) | 144 (32.3) | 144 (32.3) | |
| Primiparous (1) | 122 (27.4) | 96 (21.5) | |
| Pauciparous (2 - 3) | 108 (24.2) | 120 (26.9) | |
| Multiparous (4 - 5) | 60 (13.4) | 79 (17.7) | |
| Large Multiparous (≥6) | 12 (2.7) | 7 (1.6) | |
| Other gynecological and obstetric histories | |||
| Curettage | 31 (6.9) | 24 (5.4) | 0.330 |
| Hemorrhage of delivery | 14 (3.1) | 14 (3.1) | 0.442 |
| Myome | 12 (2.7) | 17 (3.8) | 0.345 |
| Scare uterus | 21 (4.7) | 31 (6.9) | 0.153 |
| Misoprostol, N (%) | Oxytocin, N (%) | p | |
|---|---|---|---|
| Pathologies presented during pregnancy | |||
| Hypertension/Pre-eclampsia | 98 (22.0) | 80 (17.9) | 0.131 |
| Placenta prævia | 7 (1.6) | 5 (1.1) | 0.561 |
| In Admission Pathologies | |||
| Hydramnios | 6 (1,3) | 5 (1,1) | 0.761 |
| Premature rupture of membranes | 76 (17.0) | 92 (20.6) | 0.171 |
| Severe Anemia < 7 g/dl | 3 (0.7) | 7 (1.6) | 0.340 |
| Delivery | |||
| Mean gestational age (WA) | 39.15 ± 1.53 | 39.21 ± 1.51 | 0.160 |
| Labor of spontaneous birth | 429 (96.2) | 432 (96.9) | 0.583 |
| Directed delivery | 393 (88.1) | 398 (89.2) | 0.597 |
| Natural delivery | 53 (11.9) | 48 (10.8) | |
| Average working time (hours) | 8.80 ± 2.05 | 8.83 ± 2.04 | 0.219 |
| Mean birth weight (g) | 3017 ± 515 | 3083 ± 517 | 0.603 |
± 0.27 min in the “Misoprostol” group versus 3.82 ± 0.52 min in the “Oxytocin” group (p > 0. 05). The AMTPD was a success for the majority of the parturients (98% vs 98.9%). We had only 9 cases of placental retention in the group “Misoprostol” versus 5 cases in the “Oxytocin” group. Most of the parturients had blood loss less than 500 ml (96.2% vs. 96.6%). The frequency of delivery hemorrhage was 3.8% in the “Misoprostol” group versus 3.4% in the “Oxytocin” group. The mean blood volume lost was 284.33 ± 13.31 ml in the “Misoprostol” group versus 225.94 ± 21.52 ml in the “oxytocin” group. The mean fall in hemoglobin in the “Misoprostol” group was 1.22 ± 0.11 g/dl and 0.81 ± 0.18 g/dl in the Oxytocin group (p = 0.402).The mean fall in hematocrit in the “Misoprostol” group was 2.62% ± 0.28% vs 2.34% ± 0.21% in the oxytocin group (p = 0.186). Maternal prognosis was generally good in both groups. Recorded hemorrhagic cases of the delivery had received medication and obstetrical care. No case of hemorrhage required heavy treatment (vascular ligation, hysterectomy). We had more chills, hyperthermia and nausea or vomiting in the “Misoprostol” group than in the “Oxytocin” group (
The efficiency of misoprostol versus oxytocin in the active management of the third period of childbirth was assessed through the rate of delivery, duration of placenta expulsion, blood loss.
Active management of the third period of childbirth was a success for the majority of the women in our series (98% vs 98.9%) with an average delay of placenta ejection in both groups (4.05 ± 0.27 min vs. 3.82 ± 0.52 min; p > 0.05). Our results agree with those obtained in the various studies that have addressed the importance of sublingual misoprostol in the management of the third period of
| Misoprostol, N (%) | Oxytocin, N (%) | p | |
|---|---|---|---|
| Complications of delivery | |||
| Hemorrhage from delivery | 17 (3.8) | 15 (3.4) | 0.719 |
| Placental retention | 9 (2.0) | 5 (1.1) | 0.281 |
| Atone uterine | 8 (1.8) | 10 (2.2) | 0.634 |
| Ripped cord | 7 (1.6) | 5 (1.1) | 0.561 |
| Side effects | |||
| Headache | 31 (6.9) | 21 (4.7) | 0.153 |
| Chills | 103 (23.1) | 17 (3.8) | 0.000 |
| Temperature ≥ 38˚C | 92 (20.6) | 7 (1.6) | 0.000 |
| Nausea/Vomiting | 43 (9.6) | 5 (1.1) | 0.000 |
childbirth in comparison with intramuscular oxytocin. Although the mean expulsion time varies from one study to another with variable doses of misoprostol, the results obtained are statistically identical between the group “Misoprostol” and the group “Oxytocin”. Indeed, in a double-blind randomized clinical trial conducted by Esther in Uganda between 2012 and 2013 with 600 μg misoprostol, the mean time to expulsion of the placenta was comparable (4.4 ± 2.0 min in the misoprostol group And 4.4 ± 1.9 min in the oxytocin group [
The mean blood volume lost in our series was statistically identical between the two groups (284.33 ± 13.31 ml vs 225.94 ± 21.52 ml; p> 0.05). In the literature, the mean volume of blood loss varies from one study to another, with no significant difference between the “Misoprostol” group and the “oxytocin” group (
In our series, cases of delivery hemorrhage were recorded with a frequency of 3.8% in the “Misoprostol” group versus 3.4% in the “Oxytocin” group with no significant difference. Our results are consistent with most literature data that there is no difference in the results of active management of the third period of labor with misoprostol or with oxytocin [
On the other hand, in Uganda and France, studies have reported a significantly higher frequency of delivery hemorrhage in the “Misoprostol” group than in the “Oxytocin” group (28.6% vs 17.4%; P < 0.05 [
Differences from one series to another may be related to techniques used to quantify blood loss. The main cause of delivery hemorrhage in our study was placental retention (2% vs 1.1%, p = 0.281). It is also the most common cause in the literature with no significant difference between misoprostol and oxytocin. This is the case of Benchimol (4.30% vs 5.10%, p > 0.05) [
Chills (23.1% vs. 3.8%, p < 0.05) and hyperthermia (20.6% vs. 1.6%; p < 0.05) were
| Authors | Misoprostol | Oxytocin | p |
|---|---|---|---|
| Aziz [ | 302.86 ± 160 ml | 267 ± 140 ml | 0.236 |
| Al-Harazi [ | 362 ± 170 ml | 342 ± 154 ml | >0.05 |
| Uthman [ | 327.68 ± 3.95 ml | 388.04 ± 3.95 ml | 0.26 |
| Musa [ | 325.85 ± 164.72 ml | 303.95 ± 163.33 | 0.391 |
the main side effects found in our study. These are known side effects of prostaglandins by central action, as well as nausea and vomiting [
The efficiency of misoprostol and oxytocin was comparable for the active management of the third period of labor. Misoprostol was responsible for more side effects than oxytocin. However, these side effects were mild. Misoprostol may be an alternative in Active Management of the Third Period of Delivery especially in developing countries where the cold chain is often lacking.
Aguemon, C.T., Ogoudjobi, M., Lokossou, S., Matabishi, B., King, V. and Lawansonou (2018) Efficiency and Tolerance of Misoprostol versus Oxytocin in the Active Management of the Third Period of Delivery at the University Maternity Porto-Novo, Benin. Open Journal of Obstetrics and Gynecology, 8, 321-328. https://doi.org/10.4236/ojog.2018.84035